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Introduction
• The immune system initiates
immune responses by pattern
recognition receptors (PRRs).
• Pathogen associated molecular
patterns (PAMPs) are
recognized by mechanisms
such as:
• The retinoic acid-inducible
gene I (RIG-I)-like
receptor (RLR) family.
• The toll-like receptor
(TLR) family.
• The DNA sensor cyclic
GMP-AMP (cGAMP)
synthase (cGAS).
• PAMPs induce activation of
IRF3/7 and NF-kB signaling
pathway, which results in
induction of type I interferons
(IFNs) and cytokines.
• Bulk RNA sequencing
comparing tumors with mutant
p53 and mutant p53 deletion
suggest that mutant p53
deletion impacts all three
mechanisms, however only the
cGAS mechanism has been
described in literature (Gosh at
al).

Materials and Methods
Table 1. Agonists of TLRs used and their
Pathogen Associated Molecular Patterns.

Future Work

Fig. 3 Induction of Phospho-IKKα/β in mut-p53
proficient cells by TLR 3.
Fig. 1. Overall workflow. The
experiment was conducted using Western
blot and TNFα ELISA. The incubation
periods were 3 and 24 hours respectively
after TLR agonist treatment.
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Results
• Western blot results indicate
that there is lower
phosphorylation of TBK1 in
mutant p53 cells compared to
deleted mutant p53 under
treatment of TLRs 9 and 3
(Fig.2).
• Induction of phosphorylation
of –IKKα/β in mutant p53
cells under treatment of TLR3
(Fig.3)
• TNF α production below
detection levels under
treatment of TLRs 1-9 using
ELISA (Fig.4).

Fig. 2 Higher phospho-TBK1 signaling in
p53 -/- in comparison to mut-p53.

• We are currently testing cytokine
expression of TNF-α, IFN-β,IFN-α
and IL6 using RT-PCR.
• ELISA and Western will be
conducted again to ensure
reproducibility of the data.
• Longer of incubation period for
ELISA
• Increase the number of cells per
well to 3e4 as well as increasing
the volume to 300ul per well.

•

Fig. 4. TNFα below detection levels after
TLR agonist treatment via ELISA.

Conclusions
• TLR3 induces phospho-IKK a/b
in mutant p53 proficient cells but
not in mutant p53 deleted cells
suggesting higher levels of NFkB.
• Higher phospho-TBK1 signaling
in cells without mut-p53
compared to cells with mut-p53.
• Levels of secreted TNF-α in the
supernatant in both cell lines
were below detection level via
ELISA, suggesting that more
cells per well are needed or
longer incubation time after TLR
treatment.
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